Biloba

Biloba provides an on-demand medical assistant application, connecting users with a healthcare team via instant messaging. The platform offers rapid consultations, typically within ten minutes, providing medical advice, diagnoses, and necessary prescriptions. It integrates health tracking features like vaccine schedules and growth curve monitoring for comprehensive digital management.

Founded in 2018 by Benjamin Hardy, Biloba originated from the recognized need for readily accessible medical expertise. Hardy observed the demand for immediate guidance and support for everyday health concerns, especially for families. This led to developing a digital solution democratizing access to medical professionals via a convenient, chat-based interface.

Biloba serves a broad audience, from infants through adults, addressing diverse health inquiries. The company also partners with businesses, offering its services as an employee benefit. Biloba’s vision is to be the primary digital medical assistant, providing instant, reliable, and holistic health support integrated seamlessly into daily life.

High-Level Overview

Biloba is a French digital health startup that provides on-demand medical chat consultations for parents seeking advice about their children. It builds a mobile app allowing users to text doctors, nurses, or general practitioners between 8 AM and 8 PM, addressing common parental concerns without needing a full pediatric visit.[4] The service solves the problem of quick, accessible health queries for first-time or busy parents, who often turn to unreliable forums, by offering professional responses for €10/month (waived during initial launch and lockdown).[4] Backed by Calm/Storm Ventures since 2020, Biloba operates in the digital health space with early traction of 4,000 users and 200 daily conversations within three weeks of launch.[1][4]

Origin Story

Biloba emerged in France as a solution to simplify child health management for parents. Prior to its chat service, the company released a vaccine reminder app, where users input their child's vaccine data to receive timely alerts for upcoming doses.[4] The core idea pivoted to broader telemedicine during the 2020 COVID-19 lockdown, launching a chat-based app to provide instant doctor access amid heightened parental anxieties.[4] This timing capitalized on restricted in-person visits, attracting rapid adoption without relying on video consultations, unlike competitors like Doctolib.[4] Specific founders are not detailed in available sources, but the startup quickly gained investor support from Calm/Storm Ventures, an exclusive founder network, marking a pivotal early milestone.[1]

Core Differentiators

Biloba stands out in pediatric telemedicine through these key features:

• Text-based consultations: Enables quick chats with doctors, nurses, or GPs without video, scaling easily for high demand with fewer providers.[4]
• Parent-focused niche: Targets everyday child health questions (e.g., symptoms, advice), lowering barriers versus formal visits or free national healthcare reimbursements.[4]
• Affordable subscription model: €10/month for unlimited access, bypassing France's reimbursement limits for new patients (though not covered by national health system).[4]
• Proven early momentum: Gained 4,000 users and 200 daily chats in three weeks, building on prior vaccine app success.[1][4]

Role in the Broader Tech Landscape

Biloba rides the telemedicine boom accelerated by COVID-19, particularly in digital health for family care, where parents seek frictionless advice amid forum misinformation.[4] Timing was ideal: France temporarily lifted reimbursement restrictions during lockdown, boosting adoption of non-covered services like Biloba's.[4] Favorable market forces include rising demand for scalable, async healthcare—text chats handle influxes better than video—and a gap in pediatric-specific tools beyond general platforms like Doctolib.[4] As a Calm/Storm portfolio company since 2020, it contributes to the startup ecosystem by validating niche telehealth models, potentially influencing investor focus on consumer-facing health tech in Europe.[1]

Quick Take & Future Outlook

Biloba's text-first approach positions it for growth in a post-pandemic world favoring convenient, subscription-based health tools. Next steps likely include expanding beyond France, enhancing features like vaccine integration, and navigating reimbursement hurdles for sustainability.[4] Trends like AI-assisted triage and global parental health apps will shape its path, amplifying influence if it scales user base and partnerships. Ultimately, Biloba exemplifies how targeted digital health lowers everyday barriers, evolving from lockdown novelty to essential parent ally.[1][4]